MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer that rarely develops de novo in primary tumors and is commonly acquired during the development of treatment resistance. NEPC is characterized by gain of neuroendocrine markers and loss of androgen receptor (AR), making it r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, En-Chi, Shen, Michelle, Aslan, Merve, Liu, Shiqin, Kumar, Manoj, Garcia-Marques, Fernando, Nguyen, Holly M., Nolley, Rosalie, Pitteri, Sharon J., Corey, Eva, Brooks, James D., Stoyanova, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233352/
https://www.ncbi.nlm.nih.gov/pubmed/34172788
http://dx.doi.org/10.1038/s41598-021-92552-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233352/
https://www.ncbi.nlm.nih.gov/pubmed/34172788
http://dx.doi.org/10.1038/s41598-021-92552-x

Ejemplares similares